(Press-News.org) Patients who receive more cells get significant benefits. That's a key lesson emerging from a clinical trial that was reported this week at the American Heart Association meeting in Chicago.
In this study, doctors treated heart attack patients with their own bone marrow cells, selected for their healing potential and then reinjected into the heart, in an effort to improve the heart's recovery.
In the PreSERVE-AMI phase II trial, physicians from 60 sites treated 161 patients, making the study one of the largest to assess cell therapy for heart attacks in the United States. The study was sponsored by NeoStem, Inc.
"This was an enormous undertaking, one that broke new ground in terms of assessing cell therapy rigorously," says the study's principal investigator, Arshed Quyyumi, MD, professor of medicine at Emory University School of Medicine and co-director of the Emory Clinical Cardiovascular Research Institute.
"We made some real progress in determining the cell type and doses that can benefit patients, in a group for whom the risks of progression to heart failure are high."
All participating patients received the standard of care -- stent placement -- and were only enrolled if, four days after heart attack and stenting, their ejection fraction (a measure of the heart's pumping capacity) was less than 48 percent. The average starting ejection fraction was 34 percent, a sign of severe injury to the heart.
After enrollment, patients had cells extracted from their bone marrow and received an intracoronary injection of sorted bone marrow cells or a placebo. Not all patients received the same dose of cells. Patients were supposed to receive a minimum of 10 million cells but some received more, up to 40 million.
Several previous studies of cell therapy for heart attack have used unsorted bone marrow cells. Bone marrow contains rare cells called endothelial progenitor cells, which are thought to promote healing and recovery of blood flow. In this study, extracted bone marrow cells were shipped to NeoStem's facility and a marker for endothelial progenitor cells called CD34 was used to select progenitor cells before cells were returned for intracoronary injection.
Recovery and outcomes were assessed in several ways: MACE (major adverse cardiac events, ranging from hospitalization for chest pain to death), ejection fraction, measured by magnetic resonance imaging, and perfusion or blood flow in the heart, measured by SPECT imaging. Cardiac imaging was performed six months after treatment, and MACE came from an average of twelve months of follow-up.
MACE occurred in 14 percent of control patients (n = 83), in 17 percent of those of who received less than 14 million cells (n = 47), in 10 percent of those who received greater than 14 million cells (n = 31; this includes the next group), and in 7 percent of those who received greater than 20 million cells (n = 15). Mortality was 3.6 percent in the control group, and zero in the entire treatment group.
Displaying a similar dose-dependent trend, starting from an average of 34 percent, ejection fraction increased 4.9 percent in controls, 3.1 percent in the group receiving less than 14 million cells, 5.8 percent in the group receiving more than 14 million cells, and 10.2 percent in the group receiving more than 20 million cells. There were no significant effects on improvement in blood flow in the heart, as measured by SPECT imaging.
The patients who received treatment had delays in getting stents (average 931 vs. 569 minutes), which puts the treated group at a disadvantage in terms of the heart's recovery. This was a chance effect resulting from randomization to placebo vs. treatment and not inherent to the treatment process, since all bone marrow-related treatment procedures occurred after stenting.
According to Quyyumi, FDA officials have told cell therapy investigators that MACE (clinical outcomes) are the important measure of success and SPECT imaging is not, although it provides information on mechanism. By this measure, in the group that received the most cells, the MACE rate was half that of controls. But comparing the placebo group versus the entire treatment group, there was not a significant effect on MACE.
Quyyumi says that additional follow-up should make the effect of cell therapy treatment on clinical outcomes even more clear: "It is encouraging to see clinically meaningful results this early in the study, and I look forward to future data readouts."
NeoStem executives have said that during the study, they were able to standardize their procedures so that in the future, every patient should be able to receive 20 million CD34+ cells. Quyyumi says the research team checked whether patients' pre-existing levels of CD34+ cells in their bone marrow had a significant effect on their outcomes; they did not.
"If we assume CD34 positive cells are where the action is, it's clear that you need big numbers," Quyyumi says. "This is a lesson for the cell therapy field moving forward."
INFORMATION:
Quyyumi is a member of NeoStem's advisory board. This relationship has been reviewed and approved by Emory University School of Medicine.
Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the findings may point toward potential new treatments for EoE.
"This research adds to the evidence that genetic factors play key roles in EoE, and broadens our knowledge of biological networks that may offer attractive targets for therapy," said study leader Hakon Hakonarson, M.D., Ph.D., director of the Center for Applied Genomics at The Children's Hospital of Philadelphia ...
Study says leopards stay surprisingly close to homes
Leopard home range around humans can be comparable to world's best protected areas
Article available from PLOS ONE
NEW YORK (November 21, 2014) - In the first-ever GPS-based study of leopards in India, led by WCS and partners has delved into the secret lives of these big cats, and recorded their strategies to thrive in human-dominated areas.
The study concludes that leopards in human areas are not always 'stray' or 'conflict' animals but residents, potentially requiring policy makers to rethink India's leopard-management ...
November 21, 2014 -- A study conducted by researchers at Columbia University's Mailman School of Public Health shows that obesity costs the U.S. $8.65 billion per year as a result of absenteeism in the workplace --more than 9% of all absenteeism costs. The consequences of obesity among the working population go beyond healthcare and create a financial challenge not only for the nation but for individual states as well. Findings are published online in the Journal of Occupational and Environmental Medicine.
The study is the first to provide state-level estimates of obesity-attributable ...
Lugano/Geneva, Switzerland, 21 November 2014 - New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
The novel research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. Moreover, both primary and secondary brain cancers often exhibit high expression of the immunosuppressive factor programmed cell death ligand 1 (PDL1), which can be inhibited ...
One of the most mysterious forms of life may turn out to be a rich and untapped source of antibacterial drugs.
The mysterious life form is Archaea, a family of single-celled organisms that thrive in environments like boiling hydrothermal pools and smoking deep sea vents which are too extreme for most other species to survive.
"It is the first discovery of a functional antibacterial gene in Archaea," said Seth Bordenstein, the associate professor of biological sciences at Vanderbilt University who directed the study, "You can't overstate the significance of the antibiotic ...
Prison policies vary on treating transgendered inmates, which could put inmates and institutions at risk. Gina Gibbs, a University of Cincinnati criminal justice doctoral student, will present a synopsis of the legal issues posed by such inmates at the annual meeting of the American Society of Criminology. The national conference runs from Nov. 19-22 in San Francisco.
At the center of the debate are Eighth Amendment protections against cruel and unusual punishment, widely varying policies on the treatment of transgendered populations and, Gibbs says, court crackdowns ...
CHAMPAIGN, Ill. -- Retired baseball stars Barry Bonds, Mark McGwire and Rafael Palmeiro each had Hall of Fame-worthy numbers, each hitting more than 500 home runs.
All three also were tarred by allegations of steroid use.
Their stories, however, received very different treatment over 12 years of national television news coverage, says University of Illinois professor Brian Quick, lead author on a paper about that coverage and its effects, published online Nov. 20 by the journal Communication Research.
"We found that Bonds received more than twice as many negative stories ...
This news release is available in German. One lesson that policymakers and financial regulators have drawn from the financial market crisis is that banks need to be backed by more equity. But banks have found it hard to increase their core capital positions - in other words, the equity available to them long-term. Since 2009, this has led European banks to increasingly deploy an instrument that allows them to convert debt into equity in times of need: contingent convertible bonds, also known as CoCo bonds. Banks issue these bonds at fixed interest rates - as is normal ...
Gases don't conduct heat as well as solids do. Cellular or aerated concretes take advantage of this effect, which experts call "gas-phase insulation". The heat barrier is achieved by air encased in the cavities of the concrete. But gas-phase insulation has far greater potential than keeping our homes warm. It can also be used to protect turbine engine and waste incinerator components when subjected to intense heat. All you need to do is transfer this effect to a coating that is just a few hundred micrometers thick.
Temperature differences of over 400 degrees Celsius
Scientists ...
The fixed combination of canagliflozin with metformin (trade name: Vokanamet) has been approved since April 2014 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in a dossier assessment whether the new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, because the manufacturer did not present any suitable data for any of the possible ...
